In response to the Pre-Exposure Prophylaxis Initiative (iPrEx) trial results announced in The New England Journal of Medicine in November, the Center for Global Health Policy’s blog Science Speaks recently featured reactions from several leaders in HIV/AIDS medicine, policy and advocacy. The trial studied daily oral dosing of two FDA-approved antiretroviral (ARV) medications used to treat HIV/AIDS—tenofovir and emtricitabine, combined in one tablet—for prevention of HIV among high-risk men who have sex with men. The study showed a 44 percent reduction in the incidence of HIV in those who took the drug as compared with those who took the placebo, with detectable levels of the study drug in participants’ blood strongly correlating with the prophylactic effect.
Visit the Center’s blog to read responses to the findings from Kenneth Mayer, MD, FIDSA, principal investigator at the iPrEx Fenway Health trial site; U.S. Global AIDS Coordinator Eric Goosby, MD; HIV/AIDS advocate Gregg Gonsalvez; Sten Vermund, MD, PhD, professor of medicine at the Vanderbilt School of Medicine; Cornelius Baker, HIV expert at the Academy for Educational Development; and Kaitlin Christenson, Coalition Director for the Global Health Technologies Coalition.
The HIV Medicine Association (HIVMA) also responded to the study results in a statement.
< Previous Article | Next Article >